- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.04. | Kjell Stenberg new CEO in Cyxone AB | 3 | Cision News | ||
| 28.03. | Cyxone comments on the clinical collaboration in the UK | 6 | Cision News | ||
| 25.03. | Cyxone enters important research collaboration | 4 | Cision News | ||
| 05.03. | Cyxone's CEO gives a status update | 7 | Cision News | ||
| 17.01. | Cyxone identifies target protein for rabeximod | 6 | Cision News | ||
| 15.01. | Cyxone reaches important milestone regarding mechanism of action | 5 | Cision News | ||
| 11.12.23 | Nasdaq Stockholm AB: Last day of trading in paid subscription shares (BTA) of Cyxone AB (651/23) | 265 | GlobeNewswire | Trading in Cyxone AB paid subscription shares is to cease. The last trading day
is December 12, 2023.
Short name: CYXO BTA
---------------------------
ISIN code: SE0021020450
---------------------------
Orderbook... ► Artikel lesen | |
| 07.11.23 | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Cyxone AB | 382 | GlobeNewswire | With effect from November 08, 2023, the subscription rights in Cyxone AB will
be traded on First North Growth Market. Trading will continue up until and
including November 16, 2023.
Instrument: ... ► Artikel lesen | |
| 01.11.23 | XFRA CAPITAL ADJUSTMENT INFORMATION - 01.11.2023 | 692 | Xetra Newsboard | Das Instrument 7RT FI0009006951 VALOE OYJ EQUITY wird ex Kapitalmassnahme gehandelt am 01.11.2023 The instrument 7RT FI0009006951 VALOE OYJ EQUITY is traded ex capital adjustment on 01.11.2023Das Instrument... ► Artikel lesen |
9 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,05 | -0,44 % | Minus 51% für deutsche Biotech-Branche: Sollten Sie Aktien von BioNTech, Evotec & Co dennoch kaufen? | Ein neuer Biotech-Report stellt der deutschen Branche nur in Teilen ein gutes Zeugnis aus. Langfristige Anleger könnten mit Titeln wie BioNTech oder Evotec aber dennoch auf dem richtigen Weg sein. Minus... ► Artikel lesen | |
| VALNEVA | 3,140 | -2,24 % | Valneva Aktie: Trendwende-Phantasie oder erneuter Kurssturz? | Dass die Valneva Aktie gestern an der Pariser Börse 3,5 Prozent auf 3,77 Euro zulegen konnte, darf nicht täuschen: Die Biotech-Aktie ist aktuell noch weit davon entfernt, nach hohen Verlusten die Wende... ► Artikel lesen | |
| NOVAVAX | 12,582 | -1,99 % | Novavax Aktie: Antrag für JN.1 Impfstoff eingereich | Aktualisierte COVID-19 Vakzin bald verfügbar Ein weltweit tätiges Unternehmen in der Entwicklung von proteinbasierten Impfstoffen hat kürzlich die Überarbeitung seiner Notfallzulassung für ein aktualisiertes... ► Artikel lesen | |
| AETERNA ZENTARIS | 5,540 | 0,00 % | Aeterna Zentaris Inc: Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency | Company expects to report top-line data and complete study results in Q3 2024 TORONTO, ONTARIO, June 13, 2024 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the... ► Artikel lesen | |
| BAVARIAN NORDIC | 21,040 | -0,05 % | Bavarian Nordic A/S: Bavarian Nordic Completes BLA Submission to U.S. FDA for its Chikungunya Vaccine Candidate | First regulatory submission completed for CHIKV VLP seeking approval of the vaccine candidate for immunization against chikungunya virus infection in individuals 12 years of age and olderRepresents... ► Artikel lesen | |
| BELLEROPHON THERAPEUTICS | 0,001 | -100,00 % | Delisting of Securities of SmileDirectClub, Inc.; Bellerophon Therapeutics, Inc.; Elys Game Technology; Athersys, Inc.; Borqs Technologies; ContraFect Corporation; CohBar, Inc.; AgileThought, Inc.; Fat Projects Acquisition; Evelo Biosciences ... | NEW YORK, Dec. 26, 2023 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the common stock of SmileDirectClub, Inc. SmileDirectClub, Inc.'s securities were suspended on... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 0,691 | -2,74 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging | Phio's Compound RXI-185 is designed to slow progression of UV induced collagen breakdownMarlborough, Massachusetts--(Newsfile Corp. - June 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical... ► Artikel lesen | |
| ORAGENICS | 1,560 | 0,00 % | Oragenics Appoints William "Frank" Peacock MD as Chief Clinical Officer | SARASOTA, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders... ► Artikel lesen | |
| LEXICON PHARMACEUTICALS | 1,593 | -2,57 % | Lexicon Pharmaceuticals, Inc.: Analysis of INPEFA (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology | New analysis of the pivotal Phase 3 SOLOIST-WHF trial demonstrates INPEFA cost-effectiveness Findings consistent with another study recently published in the Journal of Comparative Effectiveness... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,125 | 0,00 % | CSTONE PHARMA-B (02616): CHANGE OF JOINT COMPANY SECRETARY, PROCESS AGENT AND AUTHORIZED REPRESENTATIVE AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 ... | ||
| OUTLOOK THERAPEUTICS | 7,300 | +10,61 % | JTC Team, LLC: Outlook Therapeutics to Participate Virtual Investor Closing Bell Series | Live webcast on Thursday, June 13th at 4:00 PM ETFRENCHTOWN, NJ / ACCESSWIRE / June 12, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced... ► Artikel lesen | |
| NANOSPHERE HEALTH SCIENCES | 0,029 | 0,00 % | The Morning After: 'Nanosphere' paint could reduce a plane's CO2 emissions | ||
| GENSCRIPT BIOTECH | 1,070 | +4,90 % | GENSCRIPT BIO (01548): GRANT OF RESTRICTED SHARES | ||
| VERVE THERAPEUTICS | 5,100 | 0,00 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, May 31, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| LEAP THERAPEUTICS | 1,940 | +7,18 % | Leap Therapeutics, Inc.: Leap Therapeutics Reports First Quarter 2024 Financial Results | CAMBRIDGE, Mass., May 13, 2024 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial... ► Artikel lesen |
CYXONE AB gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -30,30 % bei einem Aktienkurs von 0,005 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
